Welcome to our dedicated page for Roivant Sciences news (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences stock.
Roivant Sciences Ltd. (Nasdaq: ROIV) generates a steady flow of news as a biopharmaceutical company focused on developing and commercializing medicines for autoimmune, inflammatory and cardiopulmonary diseases. Company updates frequently center on its late-stage clinical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as developments at its subsidiaries Priovant Therapeutics, Immunovant, Pulmovant and Genevant.
Investors following ROIV news can expect detailed coverage of clinical milestones, such as Phase 3 and Phase 2 trial readouts, proof-of-concept data and regulatory filing plans. Recent communications have highlighted positive Phase 3 VALOR results for brepocitinib in dermatomyositis, rapid enrollment in non-infectious uveitis and cutaneous sarcoidosis studies, and six-month off-treatment remission data in Graves’ disease from Immunovant’s batoclimab program. Roivant also issues news about potentially registrational trials for IMVT-1402 across several autoimmune indications and ongoing development of mosliciguat in pulmonary hypertension associated with interstitial lung disease.
Roivant’s news flow also includes quarterly and annual financial results, updates on research and development and general and administrative expenses, and information on capital allocation decisions such as common share repurchase programs. In addition, Genevant-related news may cover progress in lipid nanoparticle intellectual property litigation involving companies such as Moderna and Pfizer/BioNTech, as described in Roivant’s public updates.
This ROIV news page brings together press releases, clinical updates, financial disclosures and other company communications in one place. Readers can use it to monitor trial timelines, regulatory plans, subsidiary activities and financial reporting that Roivant discloses through its press releases and SEC filings.
Full-Life Technologies Co., Ltd. announces key executive appointments:
Roivant began trading on Nasdaq under the ticker ROIV and reported a cash balance of $2.5 billion. Dermavant presented positive results from its Phase 3 PSOARING 3 study of tapinarof for plaque psoriasis, highlighting that 58% of patients achieved a PGA score of 0 or 1 after long-term treatment. Aruvant shared encouraging data from its Phase 1/2 trial of ARU-1801 in sickle cell disease, with zero vaso-occlusive events observed for up to 18 months. Roivant's net loss was $225.6 million for the quarter, significantly up from $53.5 million year-over-year.
Roivant Sciences (Nasdaq: ROIV) has announced a quarterly investor call on November 15, 2021, at 8:00 a.m. ET to report its second quarter financial results. The company will also participate in the Jefferies London Healthcare Conference on November 17 and the Evercore ISI HealthCONx Conference on November 30. The call will be accessible via phone or webcast, with recordings available post-event. Roivant aims to enhance healthcare delivery by developing transformative medicines and technologies.
Roivant Discovery has appointed Dr. Gregory Bowman, Dr. Alex Dickson, and Dr. Paul Robustelli as the 2021 Open Science Fellows. This selection recognizes their contributions to understanding biological systems at atomic resolution. The Open Science Fellows program integrates advanced computational techniques with cutting-edge research, promoting the ethos of open science. Dr. Bowman focuses on protein dynamics, Dr. Dickson develops algorithms for molecular dynamics simulations, and Dr. Robustelli studies disordered proteins. This initiative aims to enhance predictive sciences in drug discovery at Roivant.
Roivant Sciences has successfully completed its business combination with Montes Archimedes Acquisition Corp, leading to public trading on Nasdaq under the symbols ROIV and ROIVW. The deal, finalized on September 30, 2021, results in Roivant holding approximately $2.5 billion in cash. CEO Matt Gline highlighted this merger as an opportunity to enhance value for patients and shareholders. In a strategic move, Richard Pulik has been appointed as Chief Financial Officer, bringing over 20 years of industry expertise.